INmune Bio to receive US patent for next-generation mesenchymal stromal cell product, CORDStrom: Boca Raton, Florida Saturday, April 19, 2025, 17:00 Hrs [IST] INmune Bio Inc., a c ...

Unlike traditional MSC products, CORDStrom™ comprises pooled, culture-expanded human umbilical cord-derived MSCs (hucMSCs) designed for infusion or injection, potentially offering scalable ...

The UAE’s healthcare sector has reinforced its leading position since the beginning of the year through a series of rare ...

Exosome technology has garnered significant attention in recent years due to their multifaceted functions and profound ...

INmune Bio Inc. (NASDAQ: INMB), a clinical-stage biotechnology company targeting inflammation and immunology through the innate immune system, today announced a major intellectual property milestone ...

umbilical cord, and other tissues, particularly effective in the process of tissue regeneration. The introduction of mesenchymal stem cell therapies in proctological practice has significantly ...

In January, the Abu Dhabi Stem Cells Centre reported promising results in treating Type 1 diabetes using umbilical cord-derived mesenchymal stem cell (UC-MSC) therapy. The Emirates Health Services ...